![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
No Pharmacokinetic Interaction Between HCV Inhibitors
Grazoprevir/Elbasvir with Rilpivirine
|
|
|
Clinical Pharm of HIV & Hepatitis Drug-Drug Interactions with Grazoprevir/Elbasvir: Practical Considerations for the Care of HIV/HCV Co-Infected Patients - (06/03/15)
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26 - May 28, 2015, Washington DC.
Wendy W. Yeh1, Hwa-Ping Feng1, Patrice Auger2, Zifang Guo1, Luzelena Caro1, Daria Stypinski2, John Brejda2, Patricia Jumes1, Barbara Cook2, William L. Marshall1, Marian Iwamoto1, Joan R. Butterton1
1Merck & Co., Inc., Kenilworth, NJ, USA, 2 Celerion, Lincoln, NE, USA
![Pharm1.gif](../images/060915/060815-17/Pharm1.gif)
![Pharm2.gif](../images/060915/060815-17/Pharm2.gif)
![Pharm3.gif](../images/060915/060815-17/Pharm3.gif)
![Pharm4.gif](../images/060915/060815-17/Pharm4.gif)
![Pharm5.gif](../images/060915/060815-17/Pharm5.gif)
![Pharm6.gif](../images/060915/060815-17/Pharm6.gif)
![Pharm7.gif](../images/060915/060815-17/Pharm7.gif)
![Pharm8.gif](../images/060915/060815-17/Pharm8.gif)
![Pharm9.gif](../images/060915/060815-17/Pharm9.gif)
![Pharm10.gif](../images/060915/060815-17/Pharm10.gif)
![Pharm11.gif](../images/060915/060815-17/Pharm11.gif)
![Pharm12.gif](../images/060915/060815-17/Pharm12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|